A new study in the journal JAMA Pediatrics found that less than 0.1% of adolescents in the U.S. were prescribed puberty blockers or gender-affirming hormones.

Fewer than 1 in 1,000 U.S. adolescents with commercial insurance received gender-affirming medications — puberty blockers or hormones — during a recent five-year period, according to the study released Monday.

Less than 0.1% of U.S. adolescents received drugs for gender-affirming care between 2018 and 2022, according to a study published Monday in JAMA Pediatrics. Why it matters: Critics of gender-affirming care say the drugs are experimental and dangerous and warn of their overuse,

While opponents of gender-affirming care for trans youth often act as if such care is common and undertaken thoughtlessly, it’s actually quite rare, according to a new study. The study, published Monday in JAMA Pediatrics,

Among privately insured U.S. adolescents who identified as transgender and gender-diverse (TGD), receipt of puberty blockers and hormones was rare from 2018 to 2022, according to a research letter published online Jan.